KRCA 0008

Discontinued Product

5098 has been discontinued.

View all ALK products.
说明: Potent Ack1 and ALK dual inhibitor; orally bioavailable
化学名: 1,1'-[(5-Chloro-2,4-pyrimidinediyl)bis[imino(3-methoxy-4,1-phenylene)-4,1-piperazinediyl]]bisethanone
纯度: ≥99% (HPLC)
说明书
引用文献
评论

生物活性 for KRCA 0008

KRCA 0008 is a potent Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor (IC50 values are 4 and 12 nM respectively). Inhibits lung cancer H3122 cell proliferation (IC50 = 80 nM). Attenuates H3122 cell xenograft tumor growth in mice. Orally bioavailable.

技术数据 for KRCA 0008

分子量 609.12
公式 C30H37ClN8O4
储存 Store at -20°C
纯度 ≥99% (HPLC)
CAS Number 1472795-20-2
PubChem ID 72547474
InChI Key TXDIRJCYNAWBOS-UHFFFAOYSA-N
Smiles ClC1=C(NC2=C(OC)C=C(N3CCN(C(C)=O)CC3)C=C2)N=C(NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC)N=C1

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

参考文献 for KRCA 0008

参考文献是支持产品生物活性的出版物。

Park et al (2013) Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. Bioorg.Med.Chem.Lett. 23 6192 PMID: 24095090

Lee et al (2014) ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment. Arch.Pharm.Res. 37 1130 PMID: 24446111

按产品操作查看相关产品

查看全部 ALK Inhibitors

关键词: KRCA 0008, KRCA 0008 supplier, KRCA0008, Potent, anaplastic, lymphoma, kinase, ALK, Ack1, inhibitors, inhibits, antitumor, tyrosine, kinases, orally, bioavailable, TNK2, 5098, Tocris Bioscience

篇 KRCA 0008 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 KRCA 0008 的引用文献。

KRCA 0008 的评论

目前没有该产品的评论。 Be the first to review KRCA 0008 and earn rewards!

Have you used KRCA 0008?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review